Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 0.08 below Agenus Inc's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Agenus Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 3667, from total ranking in the first quarter 2026 at 5378.

Explain Quick Ratio?
How much Cash & cash equivalents AGEN�s has?
What are AGEN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AGEN Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-1.17 %	19.65 %	46.11 %	6.09 %	-13.34 %
Y / Y Cash & cash equivalent Change	96.54 %	89.29 %	-92.59 %	-92.28 %	-89.83 %
Quick Ratio MRQ	0.08	0.14	0.01	0.01	0.04
AGEN's Total Ranking	# 3667	# 5378	# 5214	# 5003	# 4685
Seq. Current Liabilities Change	-6.99 %	-22.95 %	12.66 %	22.41 %	12.61 %
Seq. Cash & cash equivalent Change	-46.46 %	1067.31 %	-13.3 %	-63.73 %	-48.43 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 142
Healthcare Sector	# 866
Overall Market	# 3889

Quick Ratio Statistics
High	Average	Low
7.04	2.06	0.01
(Sep 30 2015)		(Dec 31 2025)

Financial Statements
Agenus Inc's Current Liabilities	$ 232 Millions	Visit AGEN's Balance sheet
Agenus Inc's Cash & cash equivalent	$ 19 Millions	Visit AGEN's Balance sheet
Source of AGEN's Sales		Visit AGEN's Sales by Geography

Cumulative Agenus Inc's Quick Ratio

AGEN's Quick Ratio for the trailling 12 Months

AGEN Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	16.77 %	12.71 %	3.41 %	-9.67 %	-4.69 %
Y / Y Cash & cash equivalent TTM Growth	-46.85 %	-74.18 %	-85.13 %	-73.11 %	-65.58 %
Quick Ratio TTM	0.06	0.05	0.03	0.08	0.12
Total Ranking TTM	# 3617	# 4348	# 3059	# 2867	# 2592
Seq. Current Liabilities TTM Growth	-0.25 %	3.89 %	10.73 %	1.76 %	-3.72 %
Seq. Cash & cash equivalent TTM Growth	18.05 %	47.88 %	-52.06 %	-36.49 %	-42.64 %

Quick ratio ranking by company, industry and sector >> Back to AGEN Financial Strength Comparisons >> Go to Compare AGEN Quick Ratio to its Competitors

On the trailing twelve months basis AGEN Cash & cash equivalent soared by 96.54 % in Q2 2026 year on year, while Current Liabilities decreased to $232 millions, this led to increase in in Agenus Inc's Quick Ratio to 0.06, Quick Ratio remained below AGEN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 143 other companies have achieved higher Quick Ratio than Agenus Inc. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3986.

Explain Quick Ratio?
How much Cash & cash equivalents AGEN�s has?
What are AGEN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 144
Healthcare Sector	# 912
Within the Market	# 3667

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.07	1.84	0.03
(Dec 31 2015)		(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
ADAPTIN BIO, INC.	0.22	$ 0.670 Millions	$ 3.036 Millions
Armata Pharmaceuticals Inc	0.10	$ 23.952 Millions	$ 250.199 Millions
Agenus Inc	0.08	$ 18.738 Millions	$ 231.820 Millions
Bioatla Inc	0.06	$ 1.544 Millions	$ 23.951 Millions
Viskase Holdings inc	0.06	$ 7.911 Millions	$ 123.630 Millions
Biomx Inc	0.06	$ 0.585 Millions	$ 10.180 Millions
Tevogen Bio Holdings Inc	0.06	$ 1.082 Millions	$ 19.573 Millions
Phoenix Biotech Acquisition Corp	0.03	$ 0.888 Millions	$ 32.405 Millions

Date modified: 2026-09-26T07:00:32+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.